Login / Signup

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.

Daniel J LovellHermine I BrunnerAndreas O ReiffLawrence JungKaterina JarosovaDana NěmcováRichard MouyChristy SandborgJohn F BohnsackDirk ElewautChristos GabrielGloria HigginsIsabelle Kone-PautOlcay Y JonesVeronika VargováElizabeth ChalomCarine WoutersIvan LagunesYanna SongAlberto MartiniNicolino Ruperto
Published in: RMD open (2021)
Through 6 years of exposure, adalimumab was well tolerated with significant clinical response (up to clinical remission) and a relatively low retention rate.
Keyphrases
  • juvenile idiopathic arthritis
  • disease activity
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • high dose
  • ulcerative colitis
  • low dose